Optimization of drug-drug interaction study design: Comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole

Drug Metabolism and Disposition

Volumn 41, Issue 7, 2013, Pages 1329-1338

  Han, Bing ^a   Mao, Jialin ^a,b   Chien, Jenny Y ^a   Hall, Stephen D ^a  

^a ELI LILLY AND COMPANY   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; KETOCONAZOLE; MIDAZOLAM;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG COMPETITION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INHIBITION; ENZYME SUBSTRATE; INTERMETHOD COMPARISON; MODEL; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PREDICTION; PRIORITY JOURNAL; PROCESS OPTIMIZATION;

AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; KETOCONAZOLE; MIDAZOLAM; MODELS, BIOLOGICAL; RESEARCH DESIGN;

EID: 84879117072     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.050732     Document Type: Article

References (23)

1. Chien JY, Lucksiri A, Ernest CS, 2nd, Gorski JC, Wrighton SA, and Hall SD (2006) Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos 34:1208-1219.
2. Chung E, Nafziger AN, Kazierad DJ, and Bertino JS, Jr (2006) Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther 79:350-361.
3. Eap CB, Buclin T, Cucchia G, Zullino D, Hustert E, Bleiber G, Golay KP, Aubert AC, Baumann P, and Telenti A, et al. (2004) Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol 60:237-246.
4. Einolf HJ (2007) Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 37:1257-1294.
5. FDA (2012) Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. http://wwwfdagov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362pdf.
6. Gibbs MA, Baillie MT, Shen DD, Kunze KL, and Thummel KE (2000) Persistent inhibition of CYP3A4 by ketoconazole in modified Caco-2 cells. Pharm Res 17:299-305.
7. Goh BC, Vokes EE, Joshi A, and RatainMJ (2002) Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours. Br J Cancer 86:534-539.
8. Guest EJ, Rowland-Yeo K, Rostami-Hodjegan A, Tucker GT, Houston JB, and Galetin A (2011) Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: Comparison of dynamic and static models. Br J Clin Pharmacol 71:72-87.
9. Krishna G, Moton A, Ma L, Savant I, Martinho M, Seiberling M, and McLeod J (2009) Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: A phase I, randomized, open-label, crossover study in healthy volunteers. Clin Ther 31:286-298.
10. Lam YW, Alfaro CL, Ereshefsky L, and Miller M (2003) Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J Clin Pharmacol 43:1274-1282.
11. Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, and Frye RF (2002) Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther 72:718-728.
12. McCrea J, Prueksaritanont T, Gertz BJ, Carides A, Gillen L, Antonello S, BruckerMJ,Miller-Stein C, Osborne B, and Waldman S (1999) Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity. J Clin Pharmacol 39:1212-1220.
13. Ohno Y, Hisaka A, and Suzuki H (2007) General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet 46:681-696.
14. Olkkola KT, Backman JT, and Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55: 481-485.
15. Peters SA, Schroeder PE, Giri N, and Dolgos H (2012) Evaluation of the use of static and dynamic models to predict drug-drug interaction and its associated variability: Impact on drug discovery and early development. Drug Metab Dispos 40:1495-1507.
16. Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, and Hamilton M (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: Computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol 64: 31-41.
17. Stoch SA, Friedman E, Maes A, Yee K, Xu Y, Larson P, Fitzgerald M, Chodakewitz J, and Wagner JA (2009) Effect of different durations of ketoconazole dosing on the singledose pharmacokinetics of midazolam: Shortening the paradigm. J Clin Pharmacol 49: 398-406.
18. Tham LS, Lee HS, Wang L, Yong WP, Fan L, Ong AB, Sukri N, Soo R, Lee SC, and Goh BC (2006) Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug. Ther Drug Monit 28:255-261.
19. Tsunoda SM, Velez RL, von Moltke LL, and Greenblatt DJ (1999) Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole. Clin Pharmacol Ther 66:461-471.
20. Yang Z, Vakkalagadda B, Shen G, Ahlers CM, Has T, Christopher LJ, Kurland JF, Roongta V, Masson E, and Zhang S (2013) Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: Assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations. J Clin Pharmacol doi: 10.1177/0091270011439208. [Epub ahead of print].
21. Yong WP, Wang LZ, Tham LS, Wong CI, Lee SC, Soo R, Sukri N, Lee HS, and Goh BC (2008) A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers. Cancer Chemother Pharmacol 62:243-251.
22. Youdim KA, Zayed A, Dickins M, Phipps A, Griffiths M, Darekar A, Hyland R, Fahmi O, Hurst S, and Plowchalk DR, et al. (2008) Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. Br J Clin Pharmacol 65:680-692.
23. Zhao P, Ragueneau-Majlessi I, Zhang L, Strong JM, Reynolds KS, Levy RH, Thummel KE, and Huang SM (2009) Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: A simulation study. J Clin Pharmacol 49:351-359.